| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 06/02/2005 | WO2005049091A2 Antibody-targeted nanoparticulate active agent delivery |
| 06/02/2005 | WO2005049005A1 Inhibitor imaging agents |
| 06/02/2005 | WO2005048987A1 Contrast medium comprising liposomes containing hydrophobic chelate compound |
| 06/02/2005 | WO2005048822A2 Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof |
| 06/02/2005 | WO2004065567A3 Brain progenitor cell-based assay, and related methods and compositions |
| 06/02/2005 | US20050120392 Using animal to identify modulators of blood coagulation; antithrombotic agents; identification and validation of platelet genes as targets for anti-thrombotic or thrombotic compounds |
| 06/02/2005 | US20050119746 Bone mineral substitute |
| 06/02/2005 | US20050119344 Based on the different degree of protection that ensure the blood-vessels of the healthy and of the tumor tissue against the influence of blood-coagulation enhancing substances; formic (methane) acid; antiseptic and bactericide |
| 06/02/2005 | US20050118165 useful for imaging such tumors; scintigraphic detection, diagnosis, prognosis, monitoring and therapy of Met-bearing tumors |
| 06/02/2005 | US20050118105 Cascade polymer bound complexing compounds, their complexes and conjugates, processes for their production, and pharmaceutical agents containing them |
| 06/02/2005 | US20050118104 For enhanced echocardiographic imaging; an injectable aqueous gas dispersion and a coadministerable vasodilator capable of diffusing into the gas |
| 06/02/2005 | US20050118103 imaging which use contrast agents that target a specific tissue or tissue component and permit the monitoring of state changes in the targeted tissue (e.g., denaturation, necrosis, tissue coagulation, apoptosis) that occur during or after interventional therapy |
| 06/02/2005 | US20050118102 Superparamagnetic nanoparticles with attached, specific targeting moiety; providing in vivo heating |
| 06/02/2005 | US20050118101 Delivery across skin or blood brain barrier; such as N-(fluorescein-5-yl)-thioureido-N'-Adoa-(polylysine)7-NH2 TFA salt |
| 06/02/2005 | US20050118100 Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent |
| 06/02/2005 | US20050118099 Thiol-mediated drug attachment to targeting peptides |
| 06/02/2005 | CA2546383A1 Rescue agents for treating botulinum toxin intoxications |
| 06/02/2005 | CA2546237A1 Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof |
| 06/02/2005 | CA2545856A1 Compositions comprising antibodies and methods of using the same for targeted nanoparticulate active agent delivery |
| 06/02/2005 | CA2545267A1 Inhibitor imaging agents |
| 06/01/2005 | EP1536020A1 Means and methods for optical determination of cAMP in vitro and in vivo |
| 06/01/2005 | EP1534990A1 Automated dynamic pressure-responsive hyperpolarized gas dispensing systems, and associated methods and computer program products |
| 06/01/2005 | EP1534702A1 Two-photon absorption heteroaromatic chromophores and compositions thereof |
| 06/01/2005 | EP1534512A1 Coated particles, methods of making and using |
| 06/01/2005 | EP1534351A1 Embolization |
| 06/01/2005 | EP1534346A2 Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues |
| 06/01/2005 | EP1534269A1 Oxime conjugates and methods for their formation and use |
| 06/01/2005 | EP1254179A4 An in vivo screen using chemical inducers of dimerization |
| 06/01/2005 | EP0883597B1 Process for the purification of an aminoalcohol |
| 06/01/2005 | CN1623001A System for monitoring bacterial tumor treatment |
| 06/01/2005 | CN1622832A Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque |
| 06/01/2005 | CN1622830A Peptide-based compounds |
| 06/01/2005 | CN1622754A Novel immune effect compound |
| 06/01/2005 | CN1620985A In vitro electro-magnetism excitation positioning system for remotely monitoring capsule swallowed in digestive tract |
| 06/01/2005 | CN1203904C Hydrophilic, lubricious medical devices having contrast with magnetic resonance imaging |
| 06/01/2005 | CN1203899C Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy |
| 06/01/2005 | CN1203898C Perfluoroalkyl-containing metal complexes, its preparing method and use in NMR diagnostics |
| 05/31/2005 | US6900301 Oligonucleotides for use in human therapeutics an diagnostics |
| 05/31/2005 | US6900026 Superoxide dismutase reduced animal model; Parkinson's disease, sepsis, amyotropic lateral sclerosis; prevent free radical damage |
| 05/31/2005 | US6899881 H. PYLORI FlbA POLYPEPTIDES, IMMUNOGENIC AND VACCINATING COMPOSITIONS COMPRISING H. PYLORI FlbA POLYPEPTIDES, AND COMPOSITIONS FOR DETECTION OF AN INFECTION COMPRISING H. PYLORI FlbA POLYPEPTIDES |
| 05/31/2005 | US6899864 Kit and method for targeting of a diagnostic or therapeutic agent to target site in mammal having a pathological condition |
| 05/26/2005 | WO2005047493A2 Nanofibrillar structure and applications including cell and tissue culture |
| 05/26/2005 | WO2005046746A2 Medical implants and fibrosis-inducing agents |
| 05/26/2005 | WO2005046735A1 A reagent system and method for modifying the luminescence of lanthanide(iii) macrocyclic complexes |
| 05/26/2005 | WO2005046734A1 Method of identifying responders to treatment with insulin sensitizers |
| 05/26/2005 | WO2005046733A1 Contrast agent for medical imaging techniques and usage thereof |
| 05/26/2005 | WO2005046722A2 Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer |
| 05/26/2005 | WO2005046573A2 Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE |
| 05/26/2005 | WO2005046563A2 Particules d’oxyde metallique magnetique pour l’irm dans les pathologies impliquant des proteinases |
| 05/26/2005 | US20050114910 Transgenic mice having a human major histocompatibility complex (MHC) phenotype, experimental uses and applications |
| 05/26/2005 | US20050113697 Method of imaging lymphatic system using nanocapsule compositions |
| 05/26/2005 | US20050113675 Ionic and non-ionic radiograhic contrast agents for use in combined x-ray and nuclear magnetic resonance diagnostics |
| 05/26/2005 | US20050113329 Contacing cell/body fluid with antibody which binds human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide; for inhibiting tumor growth; gene expression inhibition; immunization |
| 05/26/2005 | US20050113300 Method for use of pharmacological agent in the diagnosis of obsessive-compulsive disorder |
| 05/26/2005 | US20050112690 Binding molecules for the extra-domain B of fibronectin for detection of arteriosclerotic plaque |
| 05/26/2005 | US20050112675 Polypeptides gene expressed in fat tissue ; measurement concentration; using antibodies |
| 05/26/2005 | US20050112565 Proteases |
| 05/26/2005 | US20050112178 Kit for cleaning the digestive tract e.g. prior to colonoscopy or surgical procedure; provides calories for daily routine while minimizing stool formation |
| 05/26/2005 | US20050112128 Inhibition of protein kinase c-mu (PKD) as a treatment for cardiac hypertrophy and heart failure |
| 05/26/2005 | US20050112068 Systems and methods for reducing unintended use of active ingredients in dermal delivery devices |
| 05/26/2005 | US20050112065 Endocytosis sensitive detectors; reduce water permeability of liposome supplying system; liposome with detectable marking |
| 05/26/2005 | US20050112064 DNA-dependent MRI contrast agents |
| 05/26/2005 | US20050112063 Methods for inhibiting vascular permeability |
| 05/26/2005 | US20050112062 Anti-idiotypic vascular endothelial growth factor antibodies and their use as medicaments |
| 05/26/2005 | CA2545276A1 Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer |
| 05/26/2005 | CA2545066A1 A reagent system and method for modifying the luminescence of lanthanide(iii) macrocyclic complexes |
| 05/26/2005 | CA2536041A1 Medical implants and fibrosis-inducing agents |
| 05/26/2005 | CA2530605A1 Pro104 antibody compositions and methods of use |
| 05/25/2005 | EP1533619A2 Specific markers for metabolic syndrome |
| 05/25/2005 | EP1532988A2 Antibody dye conjugates for the intraoperative delimitation of tumors |
| 05/25/2005 | EP1531906A1 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor |
| 05/25/2005 | EP1531874A1 Embolization |
| 05/25/2005 | EP1531873A2 Agent delivery particle |
| 05/25/2005 | EP1531872A1 Method and apparatus for producing contrast agents for magnetic resonance imaging |
| 05/25/2005 | EP1531871A2 Method and apparatus for producing contrast agents for magnetic resonance imaging |
| 05/25/2005 | EP1531859A1 Compositions and methods for transepithelial molecular transport |
| 05/25/2005 | EP1531717A2 Magnetic resonance imaging of metal concentrations |
| 05/25/2005 | EP1261333B1 Use of topiramate for the treatment and diagnosis of sleep disordered breathing and means for carrying out the treatment and diagnosis |
| 05/25/2005 | EP1056473B1 Targeted delivery of biologically active media |
| 05/25/2005 | EP1017421B1 Use of adenoviral vectors expressing VEGF or PDGF FOR HEALING TISSUE DEFECTS AND INDUCING HYPERVASCULARITY IN MAMMALIAN TISSUE |
| 05/25/2005 | CN1620500A Corona-virus-like particles comprising functionally deleted genomes |
| 05/25/2005 | CN1620314A Gas micro-liposome compound |
| 05/25/2005 | CN1620280A 感染控制系统 Infection Control System |
| 05/25/2005 | CN1619312A Specific markers for metabolic syndrome |
| 05/25/2005 | CN1203321C Process |
| 05/25/2005 | CN1203179C DNA sequence and recombination production method of graminae allergen |
| 05/25/2005 | CN1202866C Gastrointestinal contrast agent containing biomass |
| 05/24/2005 | US6897209 Thrombosis; anticholesterol agents; cardiovascular disorders; antiinflammatory agents; anticancer agents |
| 05/24/2005 | US6897034 Antitumor agents; drug immobilized to oligopeptide; complexing; testing, calibration of complex to see if capable of being split enzyme; drug design |
| 05/24/2005 | US6896875 Mixable combination for generating a suspension of stable microbubbles for ultrasonic imaging |
| 05/24/2005 | US6896874 MR-signal emitting coatings |
| 05/24/2005 | US6896873 Includes paramagnetic metal ion- containing polymer complex that facilitates diagnostic and therapeutic techniques by readily visualizing medical devices coated with complex |
| 05/24/2005 | US6896659 Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility |
| 05/24/2005 | CA2037607C Humanised antibodies |
| 05/20/2005 | CA2487657A1 Specific markers for metabolic syndrome |
| 05/19/2005 | WO2005045041A2 Rna interference mediated inhibition of cholesteryl ester transfer protein (cetp) gene expression using short interfering nucleic acid (sina) |
| 05/19/2005 | WO2005045040A2 RNA INTERFERANCE MEDIATED INHIBITION OF CHOLINERGIC MUSCARINIC RECEPTOR (CHRM3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID /siNA) |
| 05/19/2005 | WO2005045039A2 RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/19/2005 | WO2005045032A2 RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/19/2005 | WO2005044313A2 Conjugates of angiotensin ii and an imaging moiety |